Researcher
Jurgen Joossens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Tech Transfer Office (TTO) (Research group)
Responsible
From1 Nov 2016 → Today - Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2005 → 31 Oct 2016
Projects
1 - 10 of 24
- Universal E-bike test bench to support diagnosis and quality/valuation testing of (2nd hand) electric bicycles and speed pedelecs.From1 Sep 2024 → TodayFunding: IOF - technology validation in lab
- Lifelong learning for improving quality and inclusion in childcare and leisure provision.From1 Sep 2024 → TodayFunding: IOF - technology validation in real environment
- SkillsApp, market exploration and validation of innovative web application to objectify skills evaluation.From1 May 2024 → TodayFunding: IOF - technology validation in lab
- AI-driven optimalisation of the user experience (UX) of digital tools.From1 Sep 2023 → 31 Aug 2024Funding: IOF - technology concept exploration
- CremAN: Simulating Input/Output and CAN communication for testing remanufactured automotive parts.From1 May 2023 → 30 Apr 2024Funding: IOF - technology concept exploration
- Optimization of the cryopreservation procedure of cells for therapeutic and research applications using Design of Experiments.From1 Jan 2023 → 31 Dec 2023Funding: IOF - technology concept exploration
- IOF Alliance Valorisation Manager UAntwerpen - UZAFrom7 Nov 2022 → TodayFunding: IOF - mandates
- IOF Valorisation Life SciencesFrom7 Mar 2022 → TodayFunding: IOF - mandates
- Development of a cascading approach for zero-waste valorization of agricultural and food residues.From1 Dec 2021 → 30 Nov 2023Funding: IOF - technology concept exploration
- IOF Valorisation - Project DevelopmentFrom1 Jul 2021 → TodayFunding: IOF - mandates
Publications
1 - 10 of 50
- The effect of serine protease inhibitors on visceral pain in different rodent models with an intestinal insult(2022)
Authors: Hannah Ceuleers, Nikita Hanning, Michelle De bruyn, Joris De Man, Heiko De Schepper, Qian Li, Liansheng Liu, Steven Abrams, Annemieke Smet, Jurgen Joossens, et al.
Pages: 1 - 17 - Local colonic administration of a serine protease inhibitor improves post-inflammatory visceral hypersensitivity in rats(2021)
Authors: Nikita Hanning, Michelle De bruyn, Hannah Ceuleers, Tim Boogaerts, Maya Berg, Annemieke Smet, Heiko De Schepper, Jurgen Joossens, Alexander van Nuijs, Joris De Man, et al.
- The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13 - A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation(2020)
Authors: Cedric Joossen, Adrienn Baán, Carlos Moreno Cinos, Jurgen Joossens, Nathalie Cools, Ellen Lanckacker, Lieve Moons, Kim Lemmens, Anne-Marie Lambeir, Erik Fransen, et al.
Pages: 1 - 14 - The effect of pharmacological inhibition of Serine Proteases on neuronal networks in vitro(2019)
Authors: Sebastiaan Van De Vijver, Stephan Missault, Jeroen Van Soom, Pieter Van Der Veken, Koen Augustyns, Jurgen Joossens, Stefanie Dedeurwaerdere, Michele Giugliano
Pages: 1 - 23 - α-amino diphenyl phosphonates as novel inhibitors of Escherichia coli ClpP protease(2019)
Authors: Carlos Moreno Cinos, Elisa Sassetti, Irene Garcìa Salado, Gesa Witt, Siham Benramdane, Laura Reinhardt, Cristina D. Cruz, Jurgen Joossens, Pieter Van Der Veken, Heike Broetz-Oesterhe, et al.
Pages: 774 - 797 - Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome(2018)
Authors: Hannah Ceuleers, Nikita Hanning, Leen Heirbaut, Samuel Van Remoortel, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Michelle De bruyn, Anne-Marie Lambeir, Joris De Man, et al.
Pages: 3516 - 3533 - Novel triazine dimers with potent antitrypanosomal activity(2018)
Authors: Muthusamy Venkatraj, Irene Garcìa Salado, Jan Heeres, Jurgen Joossens, Guy Caljon, Louis Maes, Pieter Van Der Veken, Koen Augustyns
Pages: 306 - 319 - Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity(2017)
Authors: Eleni Pitta, Olga Balabon, Maciej Rogacki, Jesús Gómez, Fraser Cunningham, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken, Robert Bates
Pages: 890 - 901 - Regulation of intestinal permeability: the role of proteases(2017)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Leonie Witters, Eveline Patteet, Jurgen Joossens, Koen Augustyns, Anne-Marie Lambeir, Ingrid De Meester, Joris De Man, Benedicte De Winter
Pages: 2106 - 2123
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- KLK4 inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Triazines with suitable spacers for treatment and/or prevention of HIV infections (Inventor)